Anti-Ig inactivation of the CH31 lymphoma model for immature B cell inhibits its ability to process pigeon cytochrome c

Mol Immunol. 1991 Nov;28(11):1311-4. doi: 10.1016/0161-5890(91)90018-f.

Abstract

We wished to determine whether tolerized cells are able to process and present antigen based on our hypothesis that tolerized B cells be unable to function in the normal capacity as antigen-presenting cells if they are to remain the tolerant state. Results in this study show that the ability of the murine lymphoma model for immature B cells, CH31, to process pigeon cytochrome c was greatly down-regulated when cultured in the presence of rabbit anti-mouse IgM. In contrast, the same anti-IgM treatment had no significant effect on the antigen-presenting cell function of the lymphoma model for mature B cells, CH112. Presentation of CNBr-cleaved fragments of pigeon cytochrome c by either CH31 or CH12 cells was not affected by the antibody treatment. Furthermore, CH31 cells pre-incubated with pigeon cytochrome c were not subject to the anti-IgM inhibition of the antigen presentation. These observations suggest that pertubation of surface immunoglobulin molecules on CH31 immature B cells causes down-regulation of their antigen-processing machinery.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antibodies, Anti-Idiotypic*
  • Antigen-Presenting Cells / drug effects
  • Antigen-Presenting Cells / immunology
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / immunology
  • Cell Line
  • Columbidae
  • Cytochrome c Group / metabolism*
  • Dose-Response Relationship, Immunologic
  • Down-Regulation
  • Flow Cytometry
  • Immunoglobulin M*
  • Interleukin-2 / biosynthesis
  • Lymphocyte Activation
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, B-Cell / immunology
  • Mice

Substances

  • Antibodies, Anti-Idiotypic
  • Cytochrome c Group
  • Immunoglobulin M
  • Interleukin-2